Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06850623 · ClinicalTrials.gov registry record · Phase 2
Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer
A Phase 2 study of Locally Advanced Pancreatic Adenocarcinoma, sponsored by EXACT Therapeutics AS.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 10
- Study locations
NCT06850623: Recruiting Phase 2 study of Locally Advanced Pancreatic Adenocarcinoma, sponsored by EXACT Therapeutics AS.
NCT06850623 is a Phase 2 study of Locally Advanced Pancreatic Adenocarcinoma that is actively recruiting participants, run by EXACT Therapeutics AS. The registered enrollment target is 25 participants, below the 66-participant average among 18 other Locally Advanced Pancreatic Adenocarcinoma trials with a reported enrollment target (62% lower). The trial reports 10 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06850623, a Phase 2 study of Locally Advanced Pancreatic Adenocarcinoma, is actively recruiting participants, sponsored by EXACT Therapeutics AS.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of the study is to assess the efficacy and safety of Acoustic Cluster Therapy (ACT) when given in addition to chemotherapy for treatment of Locally Advanced Pancreatic Cancer.
Conditions Studied
Interventions
- DRUG Modified FOLFIRINOX
- COMBINATION_PRODUCT Acoustic Cluster Therapy
Study Locations (10)
Pennsylvania
- Sidney Kimmel Cancer Center, Thomas Jefferson University Hospital - Philadelphia
- Allegheny General Hospital - Pittsburgh
Arizona
- HonorHealth Research Institute - Scottsdale
California
- Stanford Cancer Center Palo Alto - Stanford
Massachusetts
- Beth Israel Deaconess Medical Center - Division of Hematology/Oncology - Boston
Michigan
- Henry Ford Centre - Detroit
Rhode Island
- Brown University Cancer Institute - Providence
Cambridge
- CAMBRIDGE CANCER TRIALS CENTRE-Addenbrooke's Hospital - Cambridge
London
- Gary Weston Centre- Imperial College Healthcare- Du Cane Road - Hammersmith
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2025-06-19 |
| Est. Completion | 2027-07-15 |
| Phase | Phase 2 |
What NCT06850623 shows while recruiting
NCT06850623 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 66-participant average among 18 other Locally Advanced Pancreatic Adenocarcinoma trials with a reported enrollment target (62% lower).
The record links to 1 condition, with Locally Advanced Pancreatic Adenocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which Modified FOLFIRINOX is the first listed.
NCT06850623 lists 10 locations in 9 states (Pennsylvania, Arizona, California).
Frequently Asked Questions
What is clinical trial NCT06850623 about?
NCT06850623 is a clinical study titled "Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer". The purpose of the study is to assess the efficacy and safety of Acoustic Cluster Therapy (ACT) when given in addition to chemotherapy for treatment of Locally Advanced Pancreatic Cancer.
What is the current status of trial NCT06850623?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2025-06-19. Estimated completion is 2027-07-15.
What conditions does trial NCT06850623 study?
This clinical trial studies the following conditions: Locally Advanced Pancreatic Adenocarcinoma.
What interventions are being tested in trial NCT06850623?
The interventions under investigation include: Modified FOLFIRINOX (DRUG), Acoustic Cluster Therapy (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT06850623?
This trial is sponsored by EXACT Therapeutics AS, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06850623 being conducted?
This trial has 10 study locations across Arizona, California, Massachusetts, Michigan, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Locally Advanced Pancreatic Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06850623's enrollment target sits among peer trials
25 12th of 18 higher than 6 of 18 other Locally Advanced Pancreatic Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Locally Advanced Pancreatic Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma
RECRUITING · Phase 2
-
Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
RECRUITING · Phase 2
-
Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydrochloroquine as Treatment in Untreated Pancreas Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI